0000059478 2024-08-13 2024-08-13 0000059478 1 2024-08-13 2024-08-13 0000059478 2 2024-08-13 2024-08-13 0000059478 3 2024-08-13 2024-08-13 0000059478 4 2024-08-13 2024-08-13 0000059478 5 2024-08-13 2024-08-13 iso4217:USD pure shares 0000059478 424B2 EX-FILING FEES 0.99919 0.99781 0.99968 0.99510 0.99966 0 Eli Lilly and Company false false false false false Debt 4.150% notes due 2027 true 750000000 749392500 0.0001476 110610.33 Debt 4.200% notes due 2029 true 1000000000 997810000 0.0001476 147276.76 Debt 4.600% notes due 2034 true 1250000000 1249600000 0.0001476 184440.96 Debt 5.050% notes due 2054 true 1250000000 1243875000 0.0001476 183595.95 Debt 5.200% notes due 2064 true 750000000 749745000 0.0001476 110662.36 4990422500 736586.36 736586.36 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">These “Calculation of Filing Fee Tables” shall be deemed to update the “Calculation of Filing Fee Tables” in Eli Lilly and Company’s Registration Statement on Form <div style="white-space:nowrap;display:inline;">S-3</div> (File <div style="white-space:nowrap;display:inline;">No. 333-262943),</div> which was filed on February 24, 2022, in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">These “Calculation of Filing Fee Tables” shall be deemed to update the “Calculation of Filing Fee Tables” in Eli Lilly and Company’s Registration Statement on Form <div style="white-space:nowrap;display:inline;">S-3</div> (File <div style="white-space:nowrap;display:inline;">No. 333-262943),</div> which was filed on February 24, 2022, in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">These “Calculation of Filing Fee Tables” shall be deemed to update the “Calculation of Filing Fee Tables” in Eli Lilly and Company’s Registration Statement on Form <div style="white-space:nowrap;display:inline;">S-3</div> (File <div style="white-space:nowrap;display:inline;">No. 333-262943),</div> which was filed on February 24, 2022, in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">These “Calculation of Filing Fee Tables” shall be deemed to update the “Calculation of Filing Fee Tables” in Eli Lilly and Company’s Registration Statement on Form <div style="white-space:nowrap;display:inline;">S-3</div> (File <div style="white-space:nowrap;display:inline;">No. 333-262943),</div> which was filed on February 24, 2022, in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">These “Calculation of Filing Fee Tables” shall be deemed to update the “Calculation of Filing Fee Tables” in Eli Lilly and Company’s Registration Statement on Form <div style="white-space:nowrap;display:inline;">S-3</div> (File <div style="white-space:nowrap;display:inline;">No. 333-262943),</div> which was filed on February 24, 2022, in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. </div></td></tr></table> S-3 333-262943